PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Medunik USA (member of Duchesnay Pharmaceutical Group) is pleased to announce that an increasing number of Americans with certain urea cycle...
Health Canada Issues Recall of Medunik`s Ruzurgi (amifampridine)
BLAINVILLE, QC, Sept. 25, 2020 /CNW Telbec/ - Médunik Canada, a pharmaceutical company dedicated to improving the health and quality of life of Canadians with rare diseases, is extremely pleased to announce that its new orphan disease product Ruzurgi® (amifampridine) is now commercially available to Canadian patients.
ROSEMONT, PA, Aug. 21, 2018 /PRNewswire/ - Medunik USA, a company dedicated to improving the health and quality of life of Americans with rare diseases by making orphan drugs available in the U.S., announced today that Siklos® (hydroxyurea), an FDA-approved orphan drug, is now available in 100 mg tablets for pharmacies to order.